Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

NCT00240747 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Conditions

Gram-Positive Bacterial Infections

Interventions

DRUG: Synercid

Sponsor

Pfizer

Collaborators

[object Object]